SterRx (subsidiary of Sagent Pharmaceuticals), Plattsburgh, NY
Is SterRx (subsidiary of Sagent Pharmaceuticals) registered with the FDA as a 503B outsourcing facility?
No matching record found in FDA’s registered outsourcing facility list (updated Nov 6, 2026) on Nov 15, 2026, searching by name and location. FDA’s compounding inspections and actions page labels its entry 503B.
Does SterRx (subsidiary of Sagent Pharmaceuticals) hold a New York pharmacy license?
State pharmacy license records for New York are not checked: the Office of the Professions’ online verification search requires an access key and a check that the user is a person, and its bulk verification files are released only on request. This index reads only that state’s board actions.
Has SterRx (subsidiary of Sagent Pharmaceuticals) had a state board action or FDA letter?
FDA letters: record found. FDA’s compounding inspections and actions page, current as of Oct 22, 2026, lists 1 warning letter (Jul 27, 2022) and 1 FMD-145 letter (Jul 7, 2020) for SterRx (subsidiary of Sagent Pharmaceuticals). State board actions: no New York State Education Department action under this exact name and city was found in the New York State Education Department’s list of Board of Regents disciplinary actions against pharmacy establishments (actions dated Jan 14, 1994 to May 19, 2026) on Nov 8, 2026.
FDA registers 503B outsourcing facilities; state boards of pharmacy license pharmacies, including 503A compounding pharmacies, and keep their own disciplinary records. Neither FDA list says which drugs a pharmacy makes.
- Names in FDA records
- SterRx (subsidiary of Sagent Pharmaceuticals)
- Location
- Plattsburgh, NY
- Type as FDA labels it
- 503B
- FDA 503B list
- No matching record found
- Form 483s on FDA’s actions page
- 2
- Warning letters on FDA’s actions page
- 1
- Latest action on that page
- Jun 28, 2023
- FDA Data Dashboard inspections
- No matching site found
- State board records
- Not checked (license records); board actions matched: 0
FDA inspections and letters
FDA’s compounding inspections and actions page (current as of Oct 22, 2026) lists this pharmacy as SterRx (subsidiary of Sagent Pharmaceuticals), a 503B facility, with 4 dated actions.
| Document | |||
|---|---|---|---|
| Jun 28, 2023 | Form 483 | 483 Issued 6/28/2023 | FDA copy (archived) |
| Jul 27, 2022 | Warning letter | Warning Letter (07/27/2022) | FDA copy (archived) |
| Nov 4, 2021 | Form 483 | 483 Issued 11/04/2021 | FDA copy (archived) |
| Jul 7, 2020 | FMD-145 letter | FMD-145 Letter Issued 07/07/2020 | FDA copy (archived) |
A Form 483 lists investigator observations, not a final FDA determination. A warning letter states FDA’s view when it was issued, not a court finding; any close-out letter FDA lists is a row of its own. An untitled or FMD-145 letter states FDA’s view when it was issued.
FDA inspection classifications and published Form 483s
No inspected site under this exact name and city was found in the FDA Data Dashboard on Nov 15, 2026, searching 12,593 US sites with a drug inspection ending Oct 1, 2008 to Oct 23, 2026. FDA may list the site under another legal name, so this is not a finding that it was never inspected.
Form 483 observations
A Form 483 lists an FDA investigator’s observations at the end of an inspection. It is not a final FDA determination. In FDA’s words: “The FDA Form 483 does not constitute a final Agency determination of whether any condition is in violation of the FD&C Act or any of its relevant regulations.” (FDA Form 483 FAQ). The firm may have answered or corrected these points; a response is not shown here unless FDA lists one.
FDA links 2 Form 483 PDFs for SterRx (subsidiary of Sagent Pharmaceuticals), but no observation text is shown, for the reasons below.
Linked 483s whose text is not shown
- Jun 28, 2023: FDA document 173118: the FEI number and firm name on its cover do not match this page by the rule.
- Nov 4, 2021: FDA document 156608: the FEI number and firm name on its cover do not match this page by the rule.
State board of pharmacy records
State pharmacy license records for New York are not checked: the Office of the Professions’ online verification search requires an access key and a check that the user is a person, and its bulk verification files are released only on request. This index reads only that state’s board actions. Board actions source.
What this covers: Board of Regents disciplinary actions against pharmacy establishments from the Office of the Professions’ summaries for the pharmacy profession, which start in 1994 (105 of 105 list pages read). These are final Regents actions, mostly consent orders; open complaints and charges not yet decided are not listed. Actions against individual pharmacists are not copied. New York pharmacy licenses and registrations are not checked. Actions in the data are dated Jan 14, 1994 to May 19, 2026.
This page restates FDA’s lists and state board of pharmacy records. A Form 483, letter or board action is not a finding by this site, and a missing record is not a finding either way. A state license is matched only on the same name, city and state. Follow each link for the original document. Report an error or add a company response.
Sources
- FDA: Compounding: Inspections, Recalls, and other Actions
- FDA Registered Outsourcing Facilities (503B)
- FDA Data Dashboard: inspection classifications and published Form 483s
- New York State Education Department disciplinary records
Records last pulled Nov 15, 2026. Every entry links to the original public record.